{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:56Z","timestamp":1792787276611,"version":"4.5.0"},"reference-count":64,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"\u201dIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Cluj-Napoca, Romania","award":["project number 32153\/4\/16.12.2024"],"award-info":[{"award-number":["project number 32153\/4\/16.12.2024"]}],"id":[{"id":"https:\/\/ror.org\/051h0cw83","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>As obesity and diabetes are on the verge of an alarming growth, so is the use of tirzepatide, a novel dual glucose-dependent insulinotropic peptide\/glucagon-like peptide-1 (GLP-1) receptor agonist (RA) and currently the most effective weight loss-drug. This research aimed to identify reporting patterns related to suboptimal therapeutic outcomes and tirzepatide-related drug-use issues, mining the EudraVigilance (EV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective pharmacovigilance study using descriptive and disproportionality analyses of reports retrieved from the EV database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings<\/jats:title>\n                    <jats:p>Analysis of individual case safety reports involving tirzepatide in comparison with other GLP-1 RAs in the overall dataset (healthcare professionals (HP) and non-HP reports combined) and in the HP group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Reporting ORs (RORs) with 95% CIs for selected Preferred Terms (PT) related to drug-use issues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among all analysed PTs, the most frequently reported were \u2018Off-label use\u2019 (n=1521), \u2018Drug ineffective\u2019 (n=425) and \u2018Off-label use device\u2019 (n=99). PTs in HP reports showed lower reporting odds compared with non-HP reports. In the overall dataset, reports involving tirzepatide showed lower reporting odds of the PT \u2018Drug ineffective\u2019 than those involving liraglutide (ROR 0.61, 95%\u2009CI 0.54 to 0.70), dulaglutide (ROR 0.72, 95%\u2009CI 0.63 to 0.82), exenatide (ROR 0.78, 95%\u2009CI 0.67 to 0.92) and semaglutide (ROR 0.81, 95%\u2009CI 0.72 to 0.91). However, in HP reports, no difference in reporting odds was observed between tirzepatide and semaglutide. A different pattern was observed for \u2018off-label use\u2019 in the full dataset, with higher reporting odds for tirzepatide vs lixisenatide, dulaglutide and liraglutide, but lower reporting odds vs semaglutide (ROR 0.52, 95%\u2009CI 0.49 to 0.55). In contrast, a higher reporting odd for the PT \u2018off-label use of device\u2019 was observed for tirzepatide versus semaglutide (ROR 43.47, 95%\u2009CI 16.00 to 118.13) in the overall reports; however, this finding should be interpreted with caution given the wide CI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study complements existing evidence from clinical trials and current clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-120507","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:41:59Z","timestamp":1790862119000},"page":"e120507","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5281-5004","authenticated-orcid":false,"given":"Ioana Rada","family":"Popa Ilie","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Faculty of Medicine, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, Cluj-Napoca, CJ, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2247-4613","authenticated-orcid":false,"given":"Steliana","family":"Ghibu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, Cluj-Napoca, CJ, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1540-641X","authenticated-orcid":false,"given":"Anca","family":"Butuca","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, Lucian Blaga University of Sibiu, Sibiu, SB, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9913-1750","authenticated-orcid":false,"given":"Carmen Maximiliana","family":"Dobrea","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, Lucian Blaga University of Sibiu, Sibiu, SB, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4874-0430","authenticated-orcid":false,"given":"Adina","family":"Frum","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, Lucian Blaga University of Sibiu, Sibiu, SB, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurentiu","family":"Stoicescu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Vth Medical Clinic, Faculty of Medicine, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, Cluj-Napoca, CJ, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e3lin","family":"Homorodean","sequence":"additional","affiliation":[{"name":"Medical Clinic No. 1, Internal Medicine Department, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, Cluj-Napoca, CJ, Romania"},{"name":"Interventional Cardiology Department, Cluj-Napoca County Emergency Hospital, Cluj-Napoca, CJ, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia Gabriela","family":"Gligor","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, Lucian Blaga University of Sibiu, Sibiu, SB, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8729","authenticated-orcid":false,"given":"Claudiu","family":"Morgovan","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, Lucian Blaga University of Sibiu, Sibiu, SB, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026100106201146000_16.10.e120507.1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas 11th ed. Brussels: International Diabetes Federation, 2025."},{"key":"2026100106201146000_16.10.e120507.2","unstructured":"Katsarova I . Obesity in the eu: an ongoing epidemic. 2025. Available: https:\/\/epthinktank.eu\/2025\/03\/04\/obesity-in-the-eu-an-ongoing-epidemic\/ [Accessed 8 Mar 2026]."},{"key":"2026100106201146000_16.10.e120507.3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0360"},{"key":"2026100106201146000_16.10.e120507.4","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41416-024-02857-7","article-title":"Association of metabolic obesity phenotypes with risk of overall and site-specific cancers: a systematic review and meta-analysis of cohort studies","volume":"131","author":"Mahamat-Saleh","year":"2024","journal-title":"Br J Cancer"},{"key":"2026100106201146000_16.10.e120507.5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1402583","article-title":"Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence","volume":"15","author":"Corrao","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026100106201146000_16.10.e120507.6","doi-asserted-by":"publisher","DOI":"10.2337\/dci23-0100"},{"key":"2026100106201146000_16.10.e120507.7","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"2026100106201146000_16.10.e120507.8","unstructured":"European Medicines Agency . Mounjaro. 2022. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mounjaro [Accessed 8 Mar 2026]."},{"key":"2026100106201146000_16.10.e120507.9","unstructured":"U.S. Food and Drug Administration . FDA approves first medication for obstructive sleep apnea. 2024. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-obstructive-sleep-apnea [Accessed 8 Mar 2026]."},{"key":"2026100106201146000_16.10.e120507.10","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"2026100106201146000_16.10.e120507.11","doi-asserted-by":"crossref","DOI":"10.1155\/jobe\/3442754","article-title":"Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With \u2265 20\u2009Weeks Treatment Duration","volume":"2025","author":"Khawaji","year":"2025","journal-title":"J Obes"},{"key":"2026100106201146000_16.10.e120507.12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.17925\/EE.2024.20.2.10","article-title":"Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP\/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis","volume":"20","author":"Dutta","year":"2024","journal-title":"touchREV Endocrinol"},{"key":"2026100106201146000_16.10.e120507.13","doi-asserted-by":"crossref","first-page":"102640","DOI":"10.1016\/j.dsx.2022.102640","article-title":"Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Permana","year":"2022","journal-title":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews"},{"key":"2026100106201146000_16.10.e120507.14","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis","volume":"49","author":"Ismaiel","year":"2025","journal-title":"Int J Obes"},{"key":"2026100106201146000_16.10.e120507.15","article-title":"Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis","volume":"15","author":"Karrar","year":"2023","journal-title":"Cureus"},{"key":"2026100106201146000_16.10.e120507.16","doi-asserted-by":"crossref","DOI":"10.4239\/wjd.v16.i4.101731","article-title":"Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis","volume":"16","author":"Kamrul-Hasan","year":"2025","journal-title":"World J Diabetes"},{"key":"2026100106201146000_16.10.e120507.17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206038"},{"key":"2026100106201146000_16.10.e120507.18","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjad211"},{"key":"2026100106201146000_16.10.e120507.19","doi-asserted-by":"crossref","DOI":"10.3390\/ph19010155","article-title":"Resistance, Ineffectiveness, and Off-Label Use Related to Cephalosporins from the Reserve Group-A Pharmacovigilance Signal Detection Study on EudraVigilance Database","volume":"19","author":"Arseniu","year":"2026","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026100106201146000_16.10.e120507.20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cpt.1678","article-title":"Improving the Safety of Medicines in the European Union: From Signals to Action","volume":"107","author":"Potts","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2026100106201146000_16.10.e120507.21","unstructured":"ADR Reports . European Medicines Agency (EMA). European database of suspected adverse drug reaction reports. Available: https:\/\/www.adrreports.eu\/en\/search_subst.html [Accessed 10 Feb 2026]."},{"key":"2026100106201146000_16.10.e120507.22","unstructured":"Introductory guide meddra version 28.1. MedDRA, Available: https:\/\/alt.meddra.org\/files_acrobat\/intguide_28_1_English.pdf [Accessed 25 Feb 2026]."},{"key":"2026100106201146000_16.10.e120507.23","unstructured":"European Medicines Agency (EMA). Screening for adverse reactions in EudraVigilance, 2016. Available: https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf [Accessed 25 Feb 2026]."},{"key":"2026100106201146000_16.10.e120507.24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.40890","article-title":"Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026100106201146000_16.10.e120507.25","unstructured":"Meadowcroft O , Rickwood S , Gores M , et al . Outlook for obesity in 2026: from consolidation to acceleration. 2026. Available: https:\/\/www.iqvia.com\/locations\/emea\/blogs\/2026\/01\/outlook-for-obesity-in-2026 [Accessed 9 Mar 2026]."},{"key":"2026100106201146000_16.10.e120507.26","doi-asserted-by":"crossref","unstructured":"Liu L . A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database. Front Pharmacol 2024;15. doi:10.3389\/fphar.2024.1397029","DOI":"10.3389\/fphar.2024.1397029"},{"key":"2026100106201146000_16.10.e120507.27","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.250126"},{"key":"2026100106201146000_16.10.e120507.28","unstructured":"Loestain T , Powis J , Brinsden H , et al . World Obesity Atlas 2023."},{"key":"2026100106201146000_16.10.e120507.29","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/oby.24254","article-title":"Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program","volume":"33","author":"Tchang","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"2026100106201146000_16.10.e120507.30","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2023.100072","article-title":"Weight management treatment modalities in patients with overweight or obesity: A retrospective cohort study of administrative claims data","volume":"7","author":"Kan","year":"2023","journal-title":"Obes Pillars"},{"key":"2026100106201146000_16.10.e120507.31","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz273"},{"key":"2026100106201146000_16.10.e120507.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.10.001","article-title":"Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century","volume":"17","author":"Watson","year":"2019","journal-title":"EClinicalMedicine"},{"key":"2026100106201146000_16.10.e120507.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0494-6"},{"key":"2026100106201146000_16.10.e120507.34","first-page":"2259","article-title":"Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022\u20132025)","volume":"13","author":"Almansour","year":"2025","journal-title":"Health Care (Don Mills)"},{"key":"2026100106201146000_16.10.e120507.35","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"The Lancet"},{"key":"2026100106201146000_16.10.e120507.36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"The Lancet"},{"key":"2026100106201146000_16.10.e120507.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"2026100106201146000_16.10.e120507.38","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"2026100106201146000_16.10.e120507.39","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"The Lancet"},{"key":"2026100106201146000_16.10.e120507.40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0078"},{"key":"2026100106201146000_16.10.e120507.41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"The Lancet"},{"key":"2026100106201146000_16.10.e120507.42","doi-asserted-by":"crossref","first-page":"101805","DOI":"10.1016\/j.cegh.2024.101805","article-title":"Safety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database","volume":"30","author":"Khurana","year":"2024","journal-title":"Clin Epidemiol Glob Health"},{"key":"2026100106201146000_16.10.e120507.43","unstructured":"European Medicines Agency . Tirzepatide:summary of product characteristics (smpc). 2024."},{"key":"2026100106201146000_16.10.e120507.44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/cd22-0029","article-title":"Efficacy and Safety of Tirzepatide in Adults With Type 2 Diabetes: A Perspective for Primary Care Providers","volume":"41","author":"Kushner","year":"2023","journal-title":"Clin Diabetes"},{"key":"2026100106201146000_16.10.e120507.45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1463657","article-title":"Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups","volume":"15","author":"Ou","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026100106201146000_16.10.e120507.46","unstructured":"U.S. Food and Drug Administration . Zepbound (tirzepatide) prescribing information. 2024."},{"key":"2026100106201146000_16.10.e120507.47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/21556660.2019.1566137","article-title":"Healthcare professionals\u2019 pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates","volume":"8","author":"G\u00fcner","year":"2019","journal-title":"J Drug Assess"},{"key":"2026100106201146000_16.10.e120507.48","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13098"},{"key":"2026100106201146000_16.10.e120507.49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2050-6511-14-16","article-title":"Attitudes among healthcare professionals to the reporting of adverse drug reactions in Nepal","volume":"14","author":"Kc","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026100106201146000_16.10.e120507.50","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-017-0262-y"},{"key":"2026100106201146000_16.10.e120507.51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100106201146000_16.10.e120507.52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.14740\/jocmr6231","article-title":"Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data","volume":"17","author":"Aamir","year":"2025","journal-title":"J Clin Med Res"},{"key":"2026100106201146000_16.10.e120507.53","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/oby.24002","article-title":"Efficacy and safety of tirzepatide","volume":"32","author":"Pan","year":"2024","journal-title":"Obesity"},{"key":"2026100106201146000_16.10.e120507.54","doi-asserted-by":"crossref","DOI":"10.2196\/publichealth.9282","article-title":"Why Clinicians Don\u2019t Report Adverse Drug Events: Qualitative Study","volume":"4","author":"Hohl","year":"2018","journal-title":"JMIR Public Health Surveill"},{"key":"2026100106201146000_16.10.e120507.55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40801-018-0131-3","article-title":"An Evaluation of \u201cDrug Ineffective\u201d Postmarketing Reports in Drug Safety Surveillance","volume":"5","author":"Misu","year":"2018","journal-title":"Drugs Real World Outcomes"},{"key":"2026100106201146000_16.10.e120507.56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamainternmed.2014.6016","article-title":"Patients\u2019 expectations of the benefits and harms of treatments, screening, and tests: a systematic review","volume":"175","author":"Hoffmann","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026100106201146000_16.10.e120507.57","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000003801"},{"key":"2026100106201146000_16.10.e120507.58","unstructured":"Shalabi HS . Impact of Social Media on the Use of Weight Loss Medications. African Journal of Diabetes Medicine 2023."},{"key":"2026100106201146000_16.10.e120507.59","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051124","article-title":"An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database","volume":"12","author":"Butuca","year":"2024","journal-title":"Biomedicines"},{"key":"2026100106201146000_16.10.e120507.60","doi-asserted-by":"crossref","DOI":"10.3390\/ph16070994","article-title":"Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration\u2019s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset","volume":"16","author":"Chiappini","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026100106201146000_16.10.e120507.61","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/dom.13902","article-title":"Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)","volume":"22","author":"Matza","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026100106201146000_16.10.e120507.62","unstructured":"The Independent Pharmacy . The independent pharmacy. mounjaro: the dangers of the \u201cGolden dose. 2025. Available: https:\/\/www.theindependentpharmacy.co.uk\/weight-loss\/guides\/mounjaro-golden-dose-dangers [Accessed 10 Mar 2026]."},{"key":"2026100106201146000_16.10.e120507.63","unstructured":"Pelc C , Medical News Today . Mounjaro: what is the \u2018golden dose\u2019 and what are the risks. 2025. Available: https:\/\/www.medicalnewstoday.com\/articles\/mounjaro-golden-dose-risks-safety-weight-loss-diabetes [Accessed 10 Mar 2026]."},{"key":"2026100106201146000_16.10.e120507.64","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2025.100236","article-title":"Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol","volume":"17","author":"Duncan","year":"2026","journal-title":"Obes Pillars"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-120507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:42:12Z","timestamp":1790862132000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-120507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bmjopen-2026-120507"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-120507","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}